Hepatitis C: facts in numbers

Ono‐Nita, Suzane Kioko; Nita, Marcelo Eidi; Carrilho, Flair José

doi:10.1590/s0004-28032006000200001

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The standard treatment for patients with chronic infection is the combination of pegylated interferon α 2a/2b (PEG-INF) and ribavirin (RBV) [2]. Several criteria are used for the prognosis of the disease, including genotype, viral load, age, sex, and hepatic fibrosis [3]. …”

Section: Introductionmentioning

confidence: 99%

A Fast and Cost-Effective Method for Identifying a Polymorphism of Interleukin 28B Related to Hepatitis C

et al. 2013

Self Cite

View full text Add to dashboard Cite

Approximately 170 million people are chronic carriers of hepatitis C virus (HCV). Patients with chronic hepatitis C are currently treated with pegylated interferon and ribavirin (PEG-IFN/RBV). A genome-wide association with PEG-IFN/RBV treatment response and a single nucleotide polymorphism (rs12979860) has been identified near the interleukin 28B gene that encodes interferon-λ-3. In this paper, we describe an innovative, fast, and low-cost multiplex polymerase chain reaction with confronting two-pair primers that detects the rs12979860 polymorphism. The assay is internally controlled and does not require the use of restriction endonucleases or special equipment. Moreover, the assay decreases costs, being about 40% cheaper than direct sequencing methods.

show abstract

Section: Introductionmentioning

confidence: 99%

A Fast and Cost-Effective Method for Identifying a Polymorphism of Interleukin 28B Related to Hepatitis C

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is estimated that at least 20% of patients chronically infected would develop cirrhosis within 20 years. 1 Chronic hepatitis C has become a silent epidemic with a global impact.…”

mentioning

confidence: 99%

Hepatitis C: An overview of its laboratory diagnosis

Chander¹,

Singla²,

Garg³

2013

Journal of Gastrointestinal Infections

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a heterogeneous virus with multiple genotypes. It has a slowly progressive course with a fatal outcome. Chronic infection with HCV is a major cause of liver cancer. Diagnosing the disease early at an early stage is necessary so as to prevent its progression to chronicity. Screening for anti-HCV IgG antibody can be done by a number of immunoassays but at the same time it becomes difficult to differentiate between acute and chronic infection. To overcome this problem nucleic acid testing for detecting HCV ribonucleic acid (RNA) can be used as the mainstay for diagnosing the infection.

show abstract